Do non-steroidal anti-inflammatory drugs have a significant effect on detection and grading of ultrasound-detected synovitis in patients with rheumatoid arthritis? Results from a randomised study

Annals of the Rheumatic Diseases

Volumn 70, Issue 10, 2011, Pages 1746-1751

  Zayat, Ahmed S ^a   Conaghan, Philip G ^a   Sharif, Mohammad ^a   Freeston, Jane E ^a   Wenham, Claire ^a   Hensor, Elizabeth M A ^a   Emery, Paul ^a   Wakefield, Richard J ^a  

^a UNIVERSITY OF LEEDS   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

CELECOXIB; DICLOFENAC; ETODOLAC; ETORICOXIB; IBUPROFEN; KETOPROFEN; MEFENAMIC ACID; MELOXICAM; NAPROXEN; NONSTEROID ANTIINFLAMMATORY AGENT;

ADULT; AGED; ARTHROPATHY; ARTICLE; CLINICAL ASSESSMENT; CLINICAL TRIAL; CONTROLLED STUDY; DISEASE ACTIVITY; DISEASE DURATION; DOPPLER ECHOGRAPHY; ECHOGRAPHY; FEMALE; HAND; HEALTH STATUS; HUMAN; JOINT STIFFNESS; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; RHEUMATOID ARTHRITIS; SYMPTOMATOLOGY; SYNOVITIS; TENOSYNOVITIS; VISUAL ANALOG SCALE; WRIST;

ADULT; AGED; AGED, 80 AND OVER; ANTI-INFLAMMATORY AGENTS, NON-STEROIDAL; ARTHRITIS, RHEUMATOID; DRUG ADMINISTRATION SCHEDULE; FEMALE; FOLLOW-UP STUDIES; HAND JOINTS; HUMANS; MALE; MIDDLE AGED; SEVERITY OF ILLNESS INDEX; SYNOVIAL MEMBRANE; SYNOVITIS; ULTRASONOGRAPHY, DOPPLER; WRIST JOINT; YOUNG ADULT;

EID: 80052460906     PISSN: 00034967     EISSN: 14682060     Source Type: Journal    
DOI: 10.1136/annrheumdis-2011-200017     Document Type: Article

References (34)

1. Vane JR, Botting RM. Mechanism of action of nonsteroidal anti-inflammatory drugs. Am J Med 1998;104(3A):2S-8S; discussion 21S-22S.
2. Wakefield RJ, Green MJ, Marzo-Ortega H, et al. Should oligoarthritis be reclassified? Ultrasound reveals a high prevalence of subclinical disease. Ann Rheum Dis 2004;63:382-5.
3. Taylor PC, Steuer A, Gruber J, et al. Ultrasonographic and radiographic results from a two-year controlled trial of immediate or one-year-delayed addition of infliximab to ongoing methotrexate therapy in patients with erosive early rheumatoid arthritis. Arthritis Rheum 2006;54:47-53.
4. Døhn UM, Ejbjerg B, Boonen A, et al. No overall progression and occasional repair of erosions despite persistent inflammation in adalimumab-treated rheumatoid arthritis patients: results from a longitudinal comparative MRI, ultrasonography, CT and radiography study. Ann Rheum Dis 2011;70:252-8.
5. Naredo E, Möller I, Cruz A, et al. Power Doppler ultrasonographic monitoring of response to anti-tumor necrosis factor therapy in patients with rheumatoid arthritis. Arthritis Rheum 2008;58:2248-56.
6. Iagnocco A, Filippucci E, Perella C, et al. Clinical and ultrasonographic monitoring of response to adalimumab treatment in rheumatoid arthritis. J Rheumatol 2008;35:35-40.
7. Newman JS, Laing TJ, McCarthy CJ, et al. Power Doppler sonography of synovitis: assessment of therapeutic response-preliminary observations. Radiology 1996;198:582-4.
8. Terslev L, Torp-Pedersen S, Qvistgaard E, et al. Estimation of inflammation by Doppler ultrasound: quantitative changes after intra-articular treatment in rheumatoid arthritis. Ann Rheum Dis 2003;62:1049-53.
9. Filippucci E, Farina A, Carotti M, et al. Grey scale and power Doppler sonographic changes induced by intra-articular steroid injection treatment. Ann Rheum Dis 2004;63:740-3.
10. Teh J, Stevens K, Williamson L, et al. Power Doppler ultrasound of rheumatoid synovitis: quantification of therapeutic response. Br J Radiol 2003;76:875-9.
11. Arnett FC, Edworthy SM, Bloch DA, et al. The American Rheumatism Association 1987 revised criteria for the classification of rheumatoid arthritis. Arthritis Rheum 1988;31:315-24.
12. Shi S, Klotz U. Clinical use and pharmacological properties of selective COX-2 inhibitors. Eur J Clin Pharmacol 2008;64:233-52.
13. Todd PA, Sorkin EM. Diclofenac sodium. A reappraisal of its pharmacodynamic and pharmacokinetic properties, and therapeutic efficacy. Drugs 1988;35:244-85.
14. Naredo E, Collado P, Cruz A, et al. Longitudinal power Doppler ultrasonographic assessment of joint inflammatory activity in early rheumatoid arthritis: predictive value in disease activity and radiologic progression. Arthritis Rheum 2007;57:116-24.
15. Naredo E, Bonilla G, Gamero F, et al. Assessment of inflammatory activity in rheumatoid arthritis: a comparative study of clinical evaluation with grey scale and power Doppler ultrasonography. Ann Rheum Dis 2005;64:375-81.
16. Wakefield RJ, Balint PV, Szkudlarek M, et al. Musculoskeletal ultrasound including definitions for ultrasonographic pathology. J Rheumatol 2005;32:2485-7.
17. Brown AK, Quinn MA, Karim Z, et al. Presence of significant synovitis in rheumatoid arthritis patients with disease-modifying antirheumatic drug-induced clinical remission: evidence from an imaging study may explain structural progression. Arthritis Rheum 2006;54:3761-73.
18. Landis JR, Koch GG. The measurement of observer agreement for categorical data. Biometrics 1977;33:159-74.
19. Camacho M, López-Belmonte J, Vila L. Rate of vasoconstrictor prostanoids released by endothelial cells depends on cyclooxygenase-2 expression and prostaglandin I synthase activity. Circ Res 1998;83:353-65.
20. Vane JR, Botting RM. Anti-inflammatory drugs and their mechanism of action. Inflamm Res 1998;47 Suppl 2:S78-87.
21. Foudi N, Kotelevets L, Louedec L, et al. Vasorelaxation induced by prostaglandin E2 in human pulmonary vein: role of the EP4 receptor subtype. Br J Pharmacol 2008;154:1631-9.
22. Foudi N, Louedec L, Cachina T, et al. Selective cyclooxygenase-2 inhibition directly increases human vascular reactivity to norepinephrine during acute inflammation. Cardiovasc Res 2009;81:269-77.
23. Pap T, Distler O. Linking angiogenesis to bone destruction in arthritis. Arthritis Rheum 2005;52:1346-8.
24. Futagami S, Hiratsuka T, Shindo T, et al. COX-2 and CCR2 induced by CD40 ligand and MCP-1 are linked to VEGF production in endothelial cells. Prostaglandins Leukot Essent Fatty Acids 2008;78:137-46.
25. Brandt KD, Mazzuca SA, Buckwalter KA. Acetaminophen, like conventional NSAIDs, may reduce synovitis in osteoarthritic knees. Rheumatology (Oxford) 2006;45:1389-94.
26. Lemmel EM, Bolten W, Burgos-Vargas R, et al. Efficacy and safety of meloxicam in patients with rheumatoid arthritis. J Rheumatol 1997;24:282-90.
27. Kirchheiner B, Trang L, Wollheim FA. Diclophenax sodium (Voltaren) in rheumatoid arthritis: a double-blind comparison with indomethacin and placebo. Int J Clin Pharmacol Biopharm 1976;13:292-7.
28. Spencer-Green G. Low dose etodolac in rheumatoid arthritis: a review of early studies. J Rheumatol Suppl 1997;47:3-9;discussion 48-50.
29. Wakefield RJ, D'Agostino MA, Iagnocco A, et al. The OMERACT Ultrasound Group: status of current activities and research directions. J Rheumatol 2007;34:848-51.
30. Joshua F, de Carle R, Rayment M, et al. Power Doppler 'blanching' after the application of transducer pressure. Australas Radiol 2005;49:218-21.
31. Ellegaard K, Torp-Pedersen S, Henriksen M, et al. Influence of recent exercise and skin temperature on ultrasound Doppler measurements in patients with rheumatoid arthritis - an intervention study. Rheumatology (Oxford) 2009;48:1520-3.
32. Wynne HA, Long A, Nicholson E, et al. Are altered pharmacokinetics of non-steroidal anti-inflammatory drugs (NSAIDs) a risk factor for gastrointestinal bleeding? Br J Clin Pharmacol 1998;45:405-8.
33. Degen PH, Dieterle W, Schneider W, et al. Pharmacokinetics of diclofenac and five metabolites after single doses in healthy volunteers and after repeated doses in patients. Xenobiotica 1988;18:1449-55.
34. Hanson P, Maddison J. Non steroidal anti-inflammatory drugs and chondroprotective agents. In: Maddison JE, Page SW, Church D, eds. Small Animal Clinical Pharmacology. Second edition. London: Elsevier Health Sciences 2008:287-95.